サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1793682

爪周囲炎治療の世界市場

Paronychia Treatment

出版日
ページ情報
英文 371 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.53円
爪周囲炎治療の世界市場
出版日: 2025年08月19日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 371 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

爪周囲炎治療の世界市場は2030年までに7億180万米ドルに達する見込み

2024年に5億1,800万米ドルと推定される爪周囲炎治療の世界市場は、2024～2030年の分析期間にCAGR 5.2％で成長し、2030年には7億180万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである急性子宮内膜症は、CAGR 4.3%を記録し、分析期間終了時には4億6,190万米ドルに達すると予測されます。慢性爪周囲炎セグメントの成長率は、分析期間中CAGR 7.0%と推定されます。

米国市場は1億4,110万米ドルと推定、中国はCAGR 8.1％で成長予測

米国の爪周囲炎治療市場は、2024年に1億4,110万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを8.1%として、2030年までに1億3,870万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.6%と5.1%と予測されています。欧州では、ドイツがCAGR 3.3%で成長すると予測されています。

世界の爪周囲炎治療市場- 主要動向と促進要因のまとめ

効果的な爪周囲炎管理戦略への注目の高まりとは？

爪周囲炎は、指の爪や足の爪の周囲の皮膚に影響を及ぼす炎症性疾患で、急性型と慢性型の両方で有病率が高いため、臨床上の注目が高まっています。軽微な外傷や長時間の湿気にさらされた後の細菌、真菌、または混合感染によって一般的に引き起こされる爪周囲炎は、重大な不快感、機能制限、場合によっては膿瘍形成につながることがあります。糖尿病、免疫抑制、または刺激物への職業的曝露を有する患者における罹患率の増加により、正確な診断と時宜を得た治療に対する需要が高まっています。

治療法は、その種類と重症度によって異なります。急性の場合、抗生物質の外用または内服と、必要に応じてドレナージによる治療が行われることが多いが、慢性の場合、抗真菌療法と、刺激物への曝露を最小限に抑えるための行動修正が行われるのが一般的です。標的を絞った治療、より迅速な症状緩和、再発予防の必要性から、外来での併用療法、消毒レジメン、低侵襲手術の導入が支持されています。

急性型と慢性型の両方に対応するために、治療の選択肢はどのように進化しているか？

急性の細菌性爪周囲炎に対しては、特に蜂窩織炎がある場合には、セファレキシン、クリンダマイシン、アモキシシリンクラブラン酸塩などの経口抗生物質が一般的に使用されます。膿が貯留している場合は、無菌状態で切開排膿を行う。局所的で軽症の場合は、抗炎症作用のある抗生物質外用剤も使用されます。

慢性爪周囲炎に対する治療は、抗真菌薬、特にアゾール系またはテルビナフィン系外用薬と副腎皮質ステロイドの併用による炎症抑制にシフトしています。バリアクリームやエモリエント剤は、皮膚の完全性を回復し、湿気や刺激物への再度の暴露から保護するために処方されます。再発性または反応性の低い症例では、上皮小体化術や爪の部分的剥離術などの外科的治療が必要となります。治療レジメンは、微生物学的培養、併存疾患、患者の予防ケアへのアドヒアランスに基づいて、ますます個別化されてきています。

爪周囲炎治療の需要はどこで高まり、どの患者層が最も影響を受けるか？

プライマリケアと皮膚科クリニックの両方で、特に都市部や産業保健環境において需要が伸びています。ヘルスケア従事者、食品取扱者、水泳従事者、手洗いの習慣がある人はリスクが高いです。アトピー性皮膚炎、糖尿病、免疫抑制療法を受けている人は慢性化しやすいです。また、爪を噛んだり指をしゃぶったりする習慣がある小児患者も増加しています。

アジア太平洋とラテンアメリカの新興市場では、認知度の向上と皮膚科医療へのアクセスの拡大に伴い、診断と治療が増加しています。先進地域では、高齢化と糖尿病罹患率の増加が安定した臨床需要に寄与しています。薬局や遠隔医療プラットフォームも、特に外用薬や衛生教育で管理される軽症例や再発症例の治療アクセスに果たす役割が拡大しています。

爪周囲炎治療市場の成長は、いくつかの要因によって牽引されています。

爪周囲炎治療市場の成長は、細菌や真菌による爪感染症の有病率の上昇、職業やライフスタイルに関連したリスク要因への曝露の増加、皮膚科の健康に対する意識の拡大といった要因によって牽引されます。糖尿病人口の増加、皮膚の弱い高齢者、免疫不全患者は、急性および長期の管理を必要とする持続的な患者基盤に寄与しています。

外用療法、抗生物質・抗真菌剤配合製剤、低侵襲ドレナージ法などの進歩により、臨床成績は改善し、再発も減少しています。プライマリケアにおける早期診断とセルフケアへのシフトは、遠隔医療による診察の増加とともに、治療開始を増加させています。抗真菌剤の入手しやすさの向上、新興経済圏における皮膚科サービスへのアクセスの増加、手指や爪の衛生に関する教育の普及も、一貫した市場拡大を支えています。

セグメント

タイプ（急性爪、慢性爪）、薬剤タイプ（ムピロシン軟膏、フシジン酸軟膏、ゲンタマイシン軟膏、ジクロキサシリン）、エンドユーザー（病院・診療所、皮膚科センター）

調査対象企業の例

  • AbbVie Inc.
  • Allergen Plc（Allergan）
  • Bayer AG
  • BioNTech SE
  • ConvaTec Group Plc
  • Eli Lilly and Company
  • Fougera Pharmaceuticals Inc.
  • Galderma S.A.
  • Glenmark Generics Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Jonakayem Pharma Formulation Pvt. Ltd.
  • Merck & Co., Inc.
  • Mundipharma（with Moberg Pharma alliance）
  • NovaBay Pharmaceuticals, Inc.
  • Novartis AG
  • Perrigo New York, Inc.
  • Pfizer Inc.
  • Sandoz International GmbH
  • Taro Pharmaceutical Industries Ltd.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37660

Global Paronychia Treatment Market to Reach US$701.8 Million by 2030

The global market for Paronychia Treatment estimated at US$518.0 Million in the year 2024, is expected to reach US$701.8 Million by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Acute Paronychia, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$461.9 Million by the end of the analysis period. Growth in the Chronic Paronychia segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$141.1 Million While China is Forecast to Grow at 8.1% CAGR

The Paronychia Treatment market in the U.S. is estimated at US$141.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$138.7 Million by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Paronychia Treatment Market - Key Trends & Drivers Summarized

What Is Prompting Greater Focus on Effective Paronychia Management Strategies?

Paronychia, an inflammatory condition affecting the skin around the fingernails or toenails, is receiving increasing clinical attention due to its high prevalence across both acute and chronic forms. Commonly caused by bacterial, fungal, or mixed infections following minor trauma or prolonged moisture exposure, paronychia can lead to significant discomfort, functional limitation, and in some cases, abscess formation. The growing incidence among individuals with diabetes, immunosuppression, or occupational exposure to irritants is intensifying demand for accurate diagnosis and timely treatment.

Treatment approaches differ based on the type and severity. Acute cases are often treated with topical or oral antibiotics and drainage when necessary, while chronic paronychia typically involves antifungal therapies and behavioral modifications to minimize exposure to irritants. The need for targeted therapy, faster symptom relief, and recurrence prevention is supporting adoption of combination therapies, antiseptic regimens, and minimally invasive procedures in outpatient settings.

How Are Therapeutic Options Evolving to Address Both Acute and Chronic Forms?

For acute bacterial paronychia, oral antibiotics such as cephalexin, clindamycin, or amoxicillin-clavulanate are commonly used, especially when cellulitis is present. In cases where pus accumulation occurs, incision and drainage are performed under sterile conditions. Topical antibiotic formulations with anti-inflammatory properties are also used for localized, mild presentations.

Chronic paronychia management has shifted toward antifungal treatments, particularly topical azoles or terbinafine, combined with corticosteroids to reduce inflammation. Barrier creams and emollients are prescribed to restore skin integrity and protect against recurrent exposure to moisture and irritants. In recurrent or unresponsive cases, surgical interventions like eponychial marsupialization or partial nail avulsion may be required. Treatment regimens are increasingly personalized based on microbiological cultures, comorbid conditions, and patient adherence to preventive care.

Where Is Demand for Paronychia Treatment Growing and Which Patient Segments Are Most Affected?

Demand is growing in both primary care and dermatology clinics, particularly in urban and occupational health settings. Healthcare workers, food handlers, swimmers, and individuals with repeated hand-washing routines are at higher risk. Chronic cases are more common in those with atopic dermatitis, diabetes, or individuals on immunosuppressive therapy. Pediatric cases are also rising due to nail-biting and finger-sucking habits.

Emerging markets in Asia-Pacific and Latin America are seeing increased diagnosis and treatment as awareness improves and access to dermatological care expands. In developed regions, the aging population and higher rates of diabetes contribute to steady clinical demand. Pharmacies and telemedicine platforms are also playing a growing role in treatment access, especially for mild or recurrent cases managed with topical agents and hygiene education.

Growth in the Paronychia Treatment market is driven by several factors…

Growth in the paronychia treatment market is driven by factors such as rising prevalence of bacterial and fungal nail infections, increased exposure to occupational and lifestyle-related risk factors, and expanding awareness of dermatological health. The growing diabetic population, aging individuals with fragile skin, and immunocompromised patients contribute to a sustained patient base requiring both acute and long-term management.

Advancements in topical therapies, antibiotic-antifungal combination products, and minimally invasive drainage techniques are improving clinical outcomes and reducing recurrence. The shift toward early diagnosis and self-care in primary care settings, along with rising telehealth consultations, is increasing treatment initiation. Improved availability of antifungal agents, growing access to dermatological services in emerging economies, and wider education on hand and nail hygiene are also supporting consistent market expansion.

SCOPE OF STUDY:

The report analyzes the Paronychia Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Acute Paronychia, Chronic Paronychia); Drug Type (Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment, Dicloxacillin); End-Use (Hospitals & Clinics End-Use, Dermatology Centers End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • AbbVie Inc.
  • Allergen Plc (Allergan)
  • Bayer AG
  • BioNTech SE
  • ConvaTec Group Plc
  • Eli Lilly and Company
  • Fougera Pharmaceuticals Inc.
  • Galderma S.A.
  • Glenmark Generics Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Jonakayem Pharma Formulation Pvt. Ltd.
  • Merck & Co., Inc.
  • Mundipharma (with Moberg Pharma alliance)
  • NovaBay Pharmaceuticals, Inc.
  • Novartis AG
  • Perrigo New York, Inc.
  • Pfizer Inc.
  • Sandoz International GmbH
  • Taro Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Paronychia Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Nail Infections and Skin Disorders Spurs Demand for Effective Paronychia Treatment Options
    • Increasing Awareness of Hand and Foot Hygiene Strengthens Market for Topical and Oral Antimicrobial Therapies
    • Growing Prevalence of Chronic Conditions Such as Diabetes Throws the Spotlight on Recurrent and Complicated Paronychia Cases
    • Expansion of Dermatology Clinics and Telehealth Services Improves Access to Early Diagnosis and Prescription Treatments
    • Advancements in Antifungal and Antibacterial Drug Formulations Enhance Efficacy in Treating Both Acute and Chronic Cases
    • Rising Demand for Combination Therapies Supports the Use of Dual-Action Antibiotic and Antifungal Medications
    • Growth in At-Home Treatment Products and Over-the-Counter Creams Fuels Self-Management Among Consumers
    • Increasing Focus on Cosmetic Nail Health and Grooming Drives Demand for Preventive Treatment and Care Products
    • Surgical and Drainage Procedures for Abscess Management Expand Market for Post-Procedure Wound Care Solutions
    • Product Innovation in Moisturizing and Healing Ointments Enhances User Compliance and Recovery Outcomes
    • Rising Incidence of Occupational Nail Injuries Among Healthcare, Salon, and Construction Workers Drives Targeted Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Paronychia Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Paronychia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Paronychia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Paronychia Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Acute Paronychia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Acute Paronychia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Acute Paronychia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chronic Paronychia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chronic Paronychia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chronic Paronychia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Mupirocin Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Mupirocin Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Mupirocin Ointment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Fusidic Acid Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Fusidic Acid Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Fusidic Acid Ointment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Gentamicin Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Gentamicin Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Gentamicin Ointment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Dicloxacillin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Dicloxacillin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Dicloxacillin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Dermatology Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Dermatology Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Dermatology Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: China 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: China 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Paronychia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Paronychia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Paronychia Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: France 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: France 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Germany 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Italy 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: UK 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Spain 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Russia 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Paronychia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Paronychia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 16-Year Perspective for Paronychia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Australia 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • INDIA
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: India 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: India 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: South Korea 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Paronychia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Paronychia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Latin America 16-Year Perspective for Paronychia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Argentina 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Brazil 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Mexico 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Paronychia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Paronychia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Middle East 16-Year Perspective for Paronychia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Iran 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Israel 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: UAE 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • AFRICA
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Africa 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION